It was recently shown that the detection of tau in CSF, using a combination of an N-terminal antibody paired with a p-tau181 capture antibody, improved diagnostic accuracy for the detection of prodromal AD when compared to antibodies directed toward the mid-region domain of tau [33]. This evidence concerns the gene MAPT and Alzheimer disease.